Cocaine Dependence Clinical Trial
Official title:
Transcranial Direct Current Stimulation (tDCS) to Reduce Craving in Cocaine Addiction
Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation in
which low level electrical currents are applied to the scalp in order to alter brain
function. In the present study, tDCS will be administered with the goal of assessing the
tolerability and feasibility of this approach to 1) reduce an individual's level of drug
craving and 2) provide evidence to support the use of this device by the patient for future
unsupervised stimulation in a non-clinical setting.
Research Questions:
- Can tDCS be used successfully to train cocaine addicted individuals for
self-administration purposes?
- Can active tDCS be used to decrease drug craving in individuals with cocaine use
disorders?
- Does active tDCS outperform sham tDCS in reducing drug craving?
The ultimate goal of this project is to develop a portable neuromodulatory intervention to
reduce craving in cocaine addiction. This proposed project is in response to NIH/NIDA's
solicitation titled "Development of Portable Neuromodulatory Device for the Treatment of
Substance Use Disorders (SUDs)." The present study aims to evaluate the tolerability and
feasibility of repeated administration of tDCS to reduce drug craving in individuals with
cocaine addiction, with the aim of using these data to support a phase II study and,
ultimately, support of approval of usage of this device without clinical supervision.
The specific objectives are:
1. Establish the feasibility and safety of using tDCS to reduce self-reported cravings in
individuals addicted to cocaine.
2. Train cocaine addicted individuals to self-administer tDCS (under supervision) to test
the feasibility of future home self-administration in this population.
Substance use disorders present a treatment challenge for clinicians, as well as a
socioeconomic burden on individuals and society at large. Cocaine use disorder occurs when
someone experiences clinically significant impairment caused by the recurrent use of cocaine,
including health problems, physical withdrawal with discontinuation of use,
persistent/escalating use, and failure to meet major personal, occupational, or educational
responsibilities. At present, no FDA approved medicines are available to treat cocaine
dependence, and behavioral therapy may be used to treat this addiction, though with limited
efficacy. Drug craving (strong obsessions about and/or irresistible urges or compulsions to
consume a drug) is a central driving force for perpetuation of substance use and subsequent
addiction, as well as relapse after abstinence. Currently, no treatments exist that are
targeted at reducing drug craving, which is intrusive and distressing to patients. The
prefrontal cortex (PFC) plays an important role inhibiting these intrusive cravings. However,
decades of data have shown that PFC activity is impaired in addictions. In this study, our
goal is to increase PFC activity with non-invasive neuromodulation. Given the role of the PFC
in the processing and regulation of craving behavior, this brain region is a key target for
brain stimulation.
This study will recruit individuals with a diagnosis of cocaine use disorder (per DSM-5
criteria) who are receiving treatment for their substance use disorder at Samaritan Daytop
Village (SDV) and other similar treatment facilities (e.g., Phoenix House, Mount Sinai's
network of hospitals and clinics). Patients will be randomly assigned to receive either
active or sham (placebo) tDCS. Participants will receive 20 minutes of stimulation per tDCS
day, three days per week for five weeks.
Interviews and neuropsychological testing will be conducted, and self-reported drug craving
and addiction severity questionnaires will be used. Follow up cognitive and behavioral
assessments will be conducted over a period of 12 months post tDCS stimulation. In addition,
participants will be asked to perform EEG, cognitive tasks, and collection of a blood sample
to assess genetic/epigenetic patterns.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04994821 -
tDCS to Reduce Craving in Cocaine Addiction- Phase 2 Study
|
Phase 2 | |
Completed |
NCT01601743 -
Exercise as a Behavioral Treatment for Cocaine Dependence
|
N/A | |
Completed |
NCT01402492 -
Cocaine Use Reduction With Buprenorphine
|
Phase 2/Phase 3 | |
Completed |
NCT01176591 -
HBPL Study of the Impact of the NK1 Antagonist Aprepitant
|
Phase 2 | |
Completed |
NCT00880997 -
The Efficacy of Doxazosin for Cocaine Users
|
Phase 1 | |
Completed |
NCT00566969 -
Cocaine Withdrawal and Pharmacotherapy Response
|
N/A | |
Completed |
NCT00585520 -
Sex Differences in Progesterone Effects on Responses to Stress and Drug Cues
|
Phase 1 | |
Completed |
NCT00368290 -
Modafinil Treatment for Cocaine Dependence and HIV High-Risk Behavior
|
Phase 2 | |
Completed |
NCT00385801 -
Study of the Effects of Risperdal Consta on Brain Reward Circuitry Function, Craving and Cocaine Use in Active Cocaine Dependence
|
Phase 2 | |
Completed |
NCT00322309 -
Efficacy of Mirtazapine in Depressed Cocaine Dependent Subjects
|
Phase 2 | |
Completed |
NCT00842517 -
Long Term Maintenance of Drug Abstinence
|
Phase 1 | |
Completed |
NCT00167245 -
Topiramate for Alcohol and Cocaine Dependence
|
Phase 2 | |
Not yet recruiting |
NCT05974202 -
rTMS and Cognitive-behavioral Therapy for Cocaine Use Disorder
|
Phase 2 | |
Completed |
NCT04411914 -
Pharmaco-Magnetic Resonance Spectroscopy (MRS) Study of Clavulanic Acid
|
Phase 1 | |
Active, not recruiting |
NCT03266939 -
Rebalancing the Serotonergic System in Cocaine Dependence
|
Phase 1 | |
Completed |
NCT02563769 -
Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study
|
Phase 1 | |
Recruiting |
NCT06159387 -
Randomized, Double-blind, Placebo-controlled Cannabis Extract x Placebo for Cocaine Addicts
|
Phase 4 | |
Terminated |
NCT02935101 -
Effects of Glucocorticoids on Craving During Detoxification Treatment of Heroin and/or Stimulants
|
Phase 2 | |
Completed |
NCT02018263 -
Validation of a Remote Wireless Sensor Network (WSN) Approach to the Individualized Detection of Cocaine Use in Humans
|
Phase 1 | |
Completed |
NCT01573273 -
Oxytocin in Cocaine Dependence
|
N/A |